ArticlePathogens (Basel, Switzerland)2021
Retrospective Study of the Seroprevalence of HIV, HCV, and HBV in Blood Donors at a Blood Bank of Western Mexico.
Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- [Effectiveness of donor selection in a blood bank].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- [Screening of Hepatitis C virus in blood donors over 11 years].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Prevalence of transfusion-transmissible infections and associated sociodemographic risk factors among blood donors at a tertiary care hospital in Lahore, Pakistan.BMC infectious diseases · 2026Article
- Epidemiological Profile and Diagnostic Outcomes of Blood Donors Following Hepatitis B Screening at the Largest Blood Bank in the State of Pará, Brazil.Infectious disease reports · 2025Article
- Prevalence of Non-Viral Bloodborne Pathogens Among Healthy Blood Donors in Western Mexico: Problems and Failures of Public Health Policy.Pathogens (Basel, Switzerland) · 2024Article
- An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies.Microorganisms · 2024Review
- [Blood donor infected VHB detected by NAT probable phase in clinical resolution].Revista medica del Instituto Mexicano del Seguro Social · 2024Article
- Article
- Seroprevalence of Transmisive Diseases in Healthy Blood Donors: a Five-year Experience in University Clinical Center Tuzla.Acta informatica medica : AIM : journal of the Society for Medical Informatics of Bosnia & Herzegovina : casopis Drustva za medicinsku informatiku BiH · 2023Article
- Demographic Factors Among HIV Confirmed Blood Donors from 2013 to 2021 in Shenzhen.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Obtaining blood which is safe for transfusions is one of the principal challenges in the health systems of developing countries. Supply of contaminated blood increases morbidity, mortality, and the costs of patient care. In Mexico, serological screening is mandatory, but only a few of the main blood banks routinely perform a nucleic acid test (NAT). Data from 80,391 blood donations processed between August 2018 and December 2019 at the Central Blood Bank of the Western National Medical Center of the Mexican Social Security Institute (IMSS) were analyzed. All donors were screened for serological markers and NAT was performed. Reactive donors were followed-up to confirm their results. The number of reactive donors and seroprevalence rates for HIV, HCV, and HBV were 152 (18.91/10,000), 385 (47.89/10,000), and 181 (22.51/10,000), respectively; however, these rates decreased when NAT-confirmed reactive results were considered. Male donors were found to have a higher seroprevalence than females, and younger donors higher than older donors. The present study shows that HIV, HCV, and HBV seroprevalence in blood donors in Western Mexico is low. We propose that Mexico should establish future strategies, including pathogen reduction technologies (PRTs), in order to improve blood safety and reduce transfusion-transmissible infections (TTIs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.